Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
40results about How to "Useful in treatment of cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
InactiveUS6361774B1Strong cytotoxicityImproved profileNanomedicineAntibody ingredientsSpecific toxicitySide effect
A method for increasing the target-specific toxicity of a drug is effected by pretargeting an enzyme to a mammalian target site, and then administering a cytotoxic drug known to act at the target site or a prodrug form thereof which is converted to the drug in situ, which drug is also detoxified to form an intermediate of lower toxicity using said mammal's ordinary metabolic processes, whereby the detoxified intermediate is reconverted to its more toxic form by the pretargeted enzyme and thus has enhanced cytotoxicity at the target site. Further enhancement can be achieved by pretargeting an enzyme which converts the prodrug to the cytotoxic drug at the target site. Kits for use with the method also are provided. The method and kits permit lower doses of cytotoxic agents, maximize target site activity and minimize systemic side effects.
Owner:IMMUNOMEDICS INC
Combination therapy of antibodies against human csf-1r and tlr9 agonist
ActiveUS20140314771A1Effective activityUseful in treatment of cancerOrganic active ingredientsAntibody ingredientsAgonistCombination therapy
The present invention relates to the combination therapy of antibodies against human CSF-1R with a TLR9 agonist.
Owner:F HOFFMANN LA ROCHE & CO AG
Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist
ActiveUS9192667B2Effective activityUseful in treatment of cancerImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAgonistCombination therapy
The present invention relates to the combination therapy of antibodies against human CSF-1R with a TLR9 agonist.
Owner:F HOFFMANN LA ROCHE & CO AG
Azolidinone-vinyl fused-benzene derivatives
InactiveUS20060122176A1Inhibit telomeraseUseful in treatment of cancerAntibacterial agentsBiocideKidneyKidney disease
The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and / or prophylaxis of autoimmune disorders and / or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. Formula (I), wherein A, X, Y, Z, R1, R2 and n are as described in the description.
Owner:MERCK SERONO SA
Combination therapy and methods for treatment and prevention of hyperproliferative diseases
InactiveUS20130045179A1Prevention and treatmentSafe and well-toleratedBiocideInorganic boron active ingredientsBenign tumorSide effect
The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as HIV-AIDS, hepatitis B, hepatitis C and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects. The agents co-administered in therapeutically effective amounts are: chemotherapeutic agents, apoptotic agents, anti-angiogenic agents, cell differentiation agents, immunomodulating agents, antioxidants, vitamins, microelements, enzymes and natural extracts.
Owner:CIUSTEA MIHAI +1
Novel compounds
ActiveUS20190055232A1Useful in treatment of cancerSenses disorderNervous disorderEnzymeUbiquitin C-Terminal Hydrolase
The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and in the treatment of cancer.
Owner:MISSION THERAPEUTICS
Treatment of Cancer With a Combination of an Agent that Perturbs the EGF Signaling Pathway and an Oligonucleotide that Reduces Clusterin Levels
InactiveUS20080014198A1High expressionReduce the amount requiredOrganic active ingredientsAntibody ingredientsCancer cellApoptosis
Agents that perturb the EGF signaling pathway and that are known to be useful in the treatment of cancer are found also to result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. This is overcome using a combination of an agent that has known therapeutic efficacy against the cancer to be treated by perturbation of the EGF signaling pathway and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells small molecule inhibitor of HER-2, an antisense oligonucleotide specific for HER-2, or a peptide agent capable of interfering with HER-2 protein. The oligonucleotide may be an antisense oligonucleotide or an RNAi oligonucleotide.
Owner:THE UNIV OF BRITISH COLUMBIA
Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
ActiveUS20180215825A1Inhibit functioningReserved functionAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAmino acid bindingAntiendomysial antibodies
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
Owner:BEIGENE
Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
ActiveUS10544225B2Useful in treatment of cancerInhibit progressAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsAmino acid bindingAntiendomysial antibodies
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
Owner:BEIGENE
Pseudoglycolipid and use thereof
InactiveUS8299223B2Facilitate actionSignificant attackBiocideSugar derivativesMedicinal chemistryCancer treatment
Owner:RIKEN
Esterified alpha-galactosylceramide
InactiveUS8580751B2Reduce productionUseful in treatment of cancerBiocideSugar derivativesCarbon numberHydrogen atom
The invention provides esterified α-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I):wherein R1 is a hydrocarbon group having a carbon number of 1 to 30, R2 is a hydrocarbon group having a carbon number of 1 to 20, R3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R4 and R5 are the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or R4 and R5 in combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.
Owner:RIKEN
Method for amplifying natural killer t cells
InactiveUS20040009594A1Potent activityEffective in vitro expansionMammal material medical ingredientsArtificial cell constructsCell FractionG-csf therapy
Human Valpha24<+> natural killer T cells are expanded by culturing a mononuclear cell fraction obtainable from human peripheral blood in which hemopoietic stem cells are mobilized by granulocyte colony-stimulating factor, in the presence of a cytokine, such as interleukin 2, effecting proliferation and / or activation of lymphocytes and alpha-glycosylceramide. A cell fraction comprising human Valpha24<+> natural killer T cells expanded by the method, is useful as a cancer-treating agent.
Owner:KIRIN BREWERY CO LTD
Treatment of cancer by inhibition of IGFBP's and clusterin
InactiveUS20060122141A1High expressionReduce the amount requiredOrganic active ingredientsSugar derivativesCancer cellApoptosis
Agents that reduce the amount of IGFBP-2 and / or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this, the present invention provides a combination of therapeutic agents that is useful in the treatment of cancer. The combination includes an agent that reduces the amount of IGFBP-2 and / or IGFBP-5 and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells. In some embodiments of the invention, the agent that reduces IGFBP-2 and / or IGFBP-5 is a bispecific antisense species. The oligonucleotide may be an antisense oligonucleotide or an RNAi oligonucleotide.
Owner:THE UNIV OF BRITISH COLUMBIA
Lanthionine-related compounds for the treatment of inflammatory diseases
InactiveUS7683055B2Reduce deliveryOvercome limitationsAntibacterial agentsSenses disorderDiseaseNervous system
The present invention provides compositions comprising lanthionine ketimine derivatives and thiomorpholine dicarboxylic acid derivatives, as well as processes for the preparation of such compounds. The invention also concerns the use of lanthionine, lanthionine ketimine (LK), LK derivatives, thiomorpholine dicarboxylic acid (TMDCA), and TMDCA derivatives. It concerns the use of these compounds for the treatment and / or prevention diseases, including diseases affecting the central nervous system. The invention provides for compounds and methods having anti-oxidant, anti-neuroinflammatory and neuroprotective activities. It also provides for compounds having the ability to pass through and / or be transported through cellular membranes, such the blood-brain barrier.
Owner:OKLAHOMA MEDICAL RES FOUND
Placental preparation having antitumor activity
InactiveUS20040076618A1Effective evaluationSelective cytotoxicityBiocideMammal material medical ingredientsToxicityWilms' tumor
The present invention provides a placental preparation, its preparation method and medical uses in cancer treatments. Said placental preparation is a fraction having molecular weight less than 3 kDa obtained from a postpartum placenta of a mammal including human. The placental preparation according to the present invention has an excellent selective cytotoxicity toward tumor cells and in turn an excellent antitumor activity without any undesired side effect, and is thus very useful in cancer treatment.
Owner:YU RU CHIEN
Antitumoral treatments
InactiveUS20100323021A1High cytotoxic activityUseful in treatmentPowder deliveryImmunoglobulinsKahalalide FColloid
The present invention relates to colloidal metal nanoparticles conjugated with Kahalalide F, or an analogue thereof, and their use in the treatment of cancer. The invention also relates to a method for increasing the antitumoral activity of Kahalalide F, or an analogue thereof, which comprises conjugating the Kahalalide F, on an analogue thereof, with a colloidal metal nanoparticle.
Owner:PHARMA MAR U
4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1H)-carbonitrile derivates for treating cancer
ActiveUS20210221813A1Useful in treatment of cancerOrganic chemistryAntineoplastic agentsUbiquitin specific peptidase 7Pharmaceutical medicine
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs) and / or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to the use of DUB or desumoylating inhibitors in the treatment of cancer. Described herein are compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d each independently represent hydrogen, optionally substituted C1-C6 alkyl or R1a and R1b together form an optionally substituted C3-C6 cycloalkyl ring, or R1c and R1d together form an optionally substituted C3-C6 cycloalkyl ring; A is a 5 membered nitrogen-containing aromatic ring and is substituted with at least one optionally substituted 5 to 10 membered monocyclic or bicyclic heteroaryl or aryl ring attached through an optional linker.
![4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1H)-carbonitrile derivates for treating cancer](https://images-eureka-patsnap-com.sutd.idm.oclc.org/patent_img/da3f1b82-1ac5-454c-bf10-4f8a2210df7c/US20210221813A1-D00001.png "4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1H)-carbonitrile derivates for treating cancer")
![4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1H)-carbonitrile derivates for treating cancer](https://images-eureka-patsnap-com.sutd.idm.oclc.org/patent_img/da3f1b82-1ac5-454c-bf10-4f8a2210df7c/US20210221813A1-C00001.png "4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1H)-carbonitrile derivates for treating cancer")
![4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1H)-carbonitrile derivates for treating cancer](https://images-eureka-patsnap-com.sutd.idm.oclc.org/patent_img/da3f1b82-1ac5-454c-bf10-4f8a2210df7c/US20210221813A1-C00002.png "4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1H)-carbonitrile derivates for treating cancer")
Owner:MISSION THERAPEUTICS
Protease inhibitors
InactiveUS20120136002A1Improve securityUseful in treatment of cancerBiocideOrganic chemistryPROTEASE MProteinase activity
A compound of formula (I) wherein R1 to R15, P1, P2, A, B and Q are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as matriptase inhibitors and are useful in the treatment of matriptase dependent conditions, particularly cancer.
Owner:AURIGENE DISCOVERY TECH
Immunocompetent cell having Anti-cd38 antibody on its cell surface
An immunocompetent cell expressing an anti-CD38 antibody on its surface through genetic introduction of a DNA coding for part of the anti-CD38 antibody; and a method of producing an immunocompetent cell expressing the antibody on its cell surface, which includes amplifying a cDNA using the mRNA coding for part of the anti-CD38 antibody isolated from a hybridoma, inserting the amplified cDNA into a retroviral vector, transfecting the vector into a packaging cell to produce a packaging cell capable of producing an anti-CD38 antibody expressing-retroviral particle, and infecting a human immunocompetent cell with the retroviral particle released from the packaging cell.
Owner:HIROSHIMA UNIVERSITY
Antitumoral Compounds
ActiveUS20100280108A1Useful in treatment of cancerGroup 4/14 element organic compoundsBiocideCompound aStereochemistry
A compound of general formula (I)wherein, R11, R12, R13, R14, R15, W, Y, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.
Owner:PHARMA MAR U
Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
InactiveUS20020114808A1Improved profileUseful in treatment of cancerBiocidePeptide/protein ingredientsSpecific toxicitySide effect
Owner:IMMUNOMEDICS INC
Oxadiazole compounds, their preparation and use
InactiveUS20130005771A1Useful in treatment of cancerBiocideOrganic chemistryMyeloid leukemiaMedicine
The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.
Owner:PIRAMAL ENTERPRISES LTD
Breast cancer antigens
InactiveUS7335467B2Useful in treatment of cancerSamplingPeptide/protein ingredientsAntigenBreast cancer
The invention provides methods for diagnosing cancer including breast cancer, based on the identification of certain breast cancer-associated polypeptides as antigens that elicit immune responses in breast cancer. The identified antigens can be utilized as markers for diagnosing breast cancer, and for following the course of treatment of breast cancer.
Owner:LUDWIG INST FOR CANCER RES +2
Substituted alkyl diaryl derivatives, methods of preparation and uses
ActiveUS20150266819A1Useful in treatment of cancerBiocidePeptide/protein ingredientsArylMedicinal chemistry
Compounds according to Formula I are provided: and salts thereof, wherein Q1, Q2, R3, R4, X, and Y are as defined herein. Methods for preparing compounds of Formula I are also provided, as well as methods of treating cellular proliferative disorders, such as cancer, using compounds of Formula (I).Q2-X—Y—CHR3—CHR4-Q1 (I)
Owner:TEMPLE UNIVERSITY
Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof
InactiveUS20090191193A1Useful in treatment of cancerAntibody ingredientsImmunoglobulinsArylAntibody conjugate
Compounds useful as antiproliferative agents, including, for example, anticancer agents, according to formula I:wherein Ar1, Ar2, D, G, m and n are as defined herein, salts, antibody conjugates, pharmaceutical compositions, methods of treatment, synthetic processes, and intermediates useful in such processes are provided.
Owner:COLOPLAST AS
Cell-adhesive, enzymatically crosslinked flavonoid hydrogels and methods for making same
ActiveUS8541016B2Useful therapeutic propertyImprove anti-cancer effectAntibacterial agentsBiocideCell adhesionAdhesive
There are provided methods for producing a hydrogel that is capable of adhesion of cells and which comprises enzymatically cross-linked conjugates of a hydrogel forming agent and a flavonoid, formed from a reaction using peroxide and peroxidase. Hydrogels produced by such methods and methods of using the hydrogels are also provided.
Owner:AGENCY FOR SCI TECH & RES
Combination therapy and methods for treatment and prevention of hyperproliferative diseases
InactiveUS20150094277A1Prevention and treatmentSafe and well-toleratedBiocideInorganic boron active ingredientsDiseaseSide effect
The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as HIV-AIDS, hepatitis B, hepatitis C and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects. The agents co-administered in therapeutically effective amounts are: chemotherapeutic agents, apoptotic agents, anti-angiogenic agents, cell differentiation agents, immunomodulating agents, antioxidants, vitamins, microelements, enzymes and natural extracts.
Owner:CIUSTEA MIHAI
Mica binding agents
ActiveUS10577416B2Reduce the binding forceUseful in treatment of cancerBiological material analysisImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseMedicine
The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.
Owner:INNATE PHARMA SA
Combination therapy for breast cancer
InactiveUS9061040B2Prevention and treatmentSafe and well-toleratedOrganic active ingredientsInorganic boron active ingredientsDiseaseSide effect
The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as HIV-AIDS, hepatitis B, hepatitis C and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects. The agents co-administered in therapeutically effective amounts are: chemotherapeutic agents, apoptotic agents, anti-angiogenic agents, cell differentiation agents, immunomodulating agents, antioxidants, vitamins, microelements, enzymes and natural extracts.
Owner:CIUSTEA MIHAI
Protease inhibitors
InactiveUS8722930B2Useful in treatment of cancerPrevent intrusionBiocideOrganic chemistryHIV Protease InhibitorMedicinal chemistry
A compound of formula (I) wherein R1 to R15, P1, P2, A, B and Q are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as matriptase inhibitors and are useful in the treatment of matriptase dependent conditions, particularly cancer.
Owner:AURIGENE DISCOVERY TECH
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com